Assessing the contribution of rADAMTS13 to the treatment of congenital thrombotic thrombocytopenic purpura in Spain using Multi-Criteria Decision Analysis (MCDA)

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Assessment of rADAMTS13 improves treatment outcomes in cTTP patients, highlighting its advantages over plasma therapy.

rADAMTS13 was seen as a more effective treatment option than plasma-based therapies, improving patient quality of life significantly.
The assessment revealed significant unmet needs in cTTP management, indicating a pressing need for better therapies.
Using multi-criteria decision analysis, experts rated rADAMTS13 highly for safety, effectiveness, and cost-efficiency.
The findings suggest rADAMTS13 may reduce overall medical costs and enhance treatment accessibility for cTTP patients.

Gómez‐Seguí et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark